Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer

Related Experiment Video

Updated: May 3, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.2K

Congwen Wei1, Yuan Cao, Xiaoli Yang

  • 1State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Biotechnology, Beijing 100850, China.

Proceedings of the National Academy of Sciences of the United States of America
|January 23, 2014
PubMed

Insights

The TANK-binding kinase 1 (TBK1) promotes tamoxifen resistance in breast cancer by phosphorylating estrogen receptor alpha (ERα). High TBK1 levels correlate with poor tamoxifen response and increased relapse risk in patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Antiestrogen resistance is a significant obstacle in breast cancer treatment.
  • Estrogen receptor alpha (ERα) phosphorylation is implicated in endocrine resistance, but specific kinase roles remain unclear.

Purpose of the Study:

  • To investigate the role of TANK-binding kinase 1 (TBK1) in tamoxifen resistance in breast cancer.
  • To elucidate the mechanism by which TBK1 influences ERα activity and tamoxifen responsiveness.

Main Methods:

  • Investigated TBK1's effect on ERα transcriptional activity via phosphorylation at Ser-305.
  • Assessed tamoxifen responsiveness in breast cancer cells with ectopic TBK1 expression.
  • Correlated TBK1 expression with ERα, ERα Ser-305, and cyclin D1 in patient tumor specimens.

Main Results:

  • TBK1 enhances ERα transcriptional activity by phosphorylating ERα at Ser-305.
  • Ectopic TBK1 expression reduces breast cancer cell sensitivity to tamoxifen.
  • A positive correlation was observed between TBK1, ERα, ERα Ser-305, and cyclin D1 in patient samples.
  • High TBK1 expression in tumors predicted poor tamoxifen response and higher relapse potential.

Conclusions:

  • TBK1 is a critical factor in tamoxifen resistance in breast cancer.
  • TBK1 contributes to tamoxifen resistance through ERα phosphorylation at Ser-305.
  • TBK1 may serve as a predictive biomarker for tamoxifen treatment efficacy.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K